Proudly First In Canada
May 07, 2026
Winchester
District Memorial Hospital (WDMH) is celebrating a national milestone in heart
failure research. The hospital has officially enrolled the very first patient
in Canada in the international PRESERVED 8212 clinical trial, launching the
study in this country and putting WDMH front and centre in global heart failure
research.
Enrolling and randomizing the first patient in Canada means all required
tests have been completed and the patient has been placed into a treatment
group. Most importantly, it means a local patient now has access to a possible
new heart failure treatment through this worldwide research effort.
The
PRESERVED 8212 trial is exploring a new therapy for people living with heart
failure who continue to experience symptoms despite standard care. The goal is
to help patients feel better, improve heart function, and advance treatment
options for the future.
“This is a big moment for our hospital and our
community,” said Dr. Mohamed Gazarin, Chief Research Officer at WDMH. “Being
first in Canada highlights the strength of our research program and our
commitment to bringing leading‑edge care closer to home.”
This achievement shines a spotlight on the dedication,
teamwork, and expertise of WDMH’s research team, and reinforces the hospital’s
ongoing commitment to innovation and patient‑centred care.
To learn more about this groundbreaking research, please contact Dr.
Mohamed Gazarin, Chief Research Officer by email: mgazarin@wdmh.on.ca.
To learn more about the WDMH Research Program visit https://www.wdmh.on.ca/research.
